| 货号 | 21546-50mg |
| 描述 | Safinamide is a reversible inhibitor of monoamine oxidase B MAO-B; IC50 = 0.1 µM) that shows over 100-fold selectivity for MAO-B over MAO-A.1 It also blocks voltage-sensitive sodium channels, N- and L-type calcium channels, and glutamate and aspartate release from synaptic terminals.2,3 Safinamide is orally bioavailable and blocks a variety of seizure types in animal models.2 Formulations containing inhibitors of MAO-B, including safinamide, have benefits in the management of Parkinsons disease when combined with dopamine agonists or levodopa (L-DOPA; Item No. 13248).3,4 |
| 别名 | EMD 1195686;FCE 28073;NW-1015;PNU-151774E; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Strolin Benedetti, M.S.,Marrari, P.,Colombo, M., et al. The anticonvulsant FCE 26743 is a selective and short-acting MAO-B inhibitor devoid of inducing properties towards cytochrome P450-dependent testosterone hydroxylation in mice and rats. J. Pharm. Pharmacol. 46(10), 814-819 (1994). 2.Luszczki, J.J. Third-generation antiepileptic drugs: Mechanisms of action, pharmacokinetics and interactions. Pharmacological Reports 6, 197-216 (2009). 3.Finberg, J.P., and Rabey, J.M. Inhibitors of MAO-A and MAO-B in psychiatry and neurology. Front. Pharmacol. 7, 340 (2016). 4.Müller, T. Emerging approaches in Parkinson’s disease - adjunctive role of safinamide. Ther. Clin. Risk Manag. 12, 1151-1160 (2016). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 398.4 |
| 分子式 | C17H19FN2O2 • CH3SO3H |
| CAS号 | 202825-46-5 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |